Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
5(71%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_1
1
14%
Ph phase_2
2
29%
Ph phase_3
4
57%

Phase Distribution

1

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
4(57.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

7

all time

Status Distribution
Active(5)
Completed(2)

Detailed Status

Active, not recruiting3
Recruiting2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 22 (28.6%)
Phase 34 (57.1%)

Trials by Status

active_not_recruiting343%
recruiting229%
completed229%

Recent Activity

5 active trials
Showing 5 of 7
active_not_recruitingphase_1

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

NCT05249426
active_not_recruitingphase_3

A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China

NCT07226752
active_not_recruitingphase_3

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

NCT04628494
recruitingphase_3

A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

NCT05652894
recruitingphase_3

A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

NCT06732323
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05249426Phase 1

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Active Not Recruiting
NCT07226752Phase 3

A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China

Active Not Recruiting
NCT04628494Phase 3

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Active Not Recruiting
NCT05652894Phase 3

A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Recruiting
NCT06732323Phase 3

A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Recruiting
NCT03023878Phase 2

Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma

Completed
NCT01156753Phase 2

A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer

Completed

All 7 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
7